High T-cell infiltration in tumor tissue and younger age predict the response to pembrolizumab in recurrent urothelial cancer

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

(2020) Ronja Morsch et al.   BMC CANCER

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

(2020) Matthew D Galsky et al.   LANCET

Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer

(2020) David Y. Oh et al.   CELL

Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma

(2020) Yoshiaki Yamamoto et al.   International Journal of Clinical Oncology

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

(2019) Y Fradet et al.   ANNALS OF ONCOLOGY

MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series

(2019) Selma Ugurel et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma

(2019) Magdalena Zajac et al.   Diagnostic Pathology

Bladder Cancer Exhibiting High Immune Infiltration Shows the Lowest Response Rate to Immune Checkpoint Inhibitors

(2019) Shen Pan et al.   Frontiers in Oncology

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

(2017) Scott Gettinger et al.   Cancer Discovery

Bladder Cancer

(2017) Peter E. Clark et al.   Journal of the National Comprehensive Cancer Network

Molecular biology and targeted therapies for urothelial carcinoma

(2015) Emmanuel Seront et al.   CANCER TREATMENT REVIEWS

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients

(2013) E C M Zeestraten et al.   BRITISH JOURNAL OF CANCER

Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

(2011) Maria De Santis et al.   JOURNAL OF CLINICAL ONCOLOGY

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine